ClinicalTrials.gg
CompletedNCT02739672Updated Jan 26, 2017

Clinical Trial to Compare the Pharmacokinetics of TAH Tablet in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers

A Phase 1 interventional study of TAH Tablet (Telmisartan/Amlodipine besylate/Hydrochlorothiazide) and TWYNSTA(Telmisartan+Amlodipine besylate) in Healthy, sponsored by IlDong Pharmaceutical Co Ltd. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-01-26.

Sponsored by IlDong Pharmaceutical Co Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
Male
01

Study summary

randomized, open-label, single dose, replicate crossover clinical trial to compare the pharmacokinetics of TAH tablet in comparison to the co-administration of telmisartan, amlodipine and hydrochlorothiazide in healthy male volunteers

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

IlDong Pharmaceutical Co Ltd is the lead sponsor of 50 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male volunteers aged 19 to 55 years
  2. (BMI) of 17.5-30.5kg/m2 and weigh more than 55kg
  3. Subject does not have congenital or chronic disease and is without pathologic symptom or finding on medical exam.
  4. Subject was determined eligible according to the results of clinical laboratory tests like serum test, hematologic test, blood chemistry test, urine test etc. and vital signs, electrocardiography, physical exam etc. performed during the screening exam. 5) willing and able to provide written

Exclusion criteria

Exclusion Criteria:

  1. Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)
  2. A subject with a history of gastrointestinal disease or surgery (except simple appendectomy or repair of hernia), which can influence the absorption of the study drug
  3. History of regular alcohol consumption (> 210 g/week) within the 6 months before the screening visit.
  4. Subjects who take the medication involved in other clinical trials or bioequivalence tests within three months before the first dose medication characters.
  5. Seated systolic blood pressure \<100mmHg or ≥ 150 mmHg , or diastolic blood pressure of \<600mmHg or ≥ 100mmHg at the screening visit
  6. History of alcohol or drug abuse within the 12 months before the screening visit
  7. Subjects who treated with metabolizing enzyme inducers or inhibitors such as barbitals within 30days prior to the first dosing.
  8. Smoker who smoke more than 20 cigarettes per day
  9. Subjects who take ethical the count or over the count medicine within 10days before the first product administration.
  10. Blood Subjects who do the whole blood donation within two months or component blood donation within 1month prior to the first dosing.
  11. Subjects who can increase risk due to clinical test and administration of drugs or has Severe grade / chronic medical, mental condition or abnormal laboratory result that may interfere with the analysis of test results.
  12. Subject with known for reaction to TWYNSTA TAB or dihydropyridine derivatives
  13. Subject with known for hypersensitivity reaction to thiazide diuretics or Sulfonamides
  14. Patients with biliary obstructive disorder
  15. Patients receiving other drugs that affect RAAS such as Angiotensin Receptor Blocker(ARB), ACE inhibitors or aliskiren
  16. Combination with aliskiren in Diabetic patient or moderate to severe renal insufficient subjects (\<60mL/min/1.73m2)
  17. Patients with severe hepatic impairment
  18. Patients with severe aortic stenosis
  19. Patients with history of shock
  20. Patients with anuria
  21. Patients with acute or severe renal failure
  22. Patients with hyponatraemia hypokalemia
  23. Patients with Addison's disease
  24. Patients with hypercalcemia of
  25. Who has Galactose intolerance, LAPP lactose intolerance, glucose-galactose malabsorption or genetic disorders
  26. Test subjects who is not willing or unable to comply with guidelines described in this protocol
  27. A person who is not determined unsuitable to participate in this test by the researchers
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    TAH tablet

    Telmisartan/Amlodipine besylate/Hydrochlorothiazide tablet

    Drug: TAH Tablet (Telmisartan/Amlodipine besylate/Hydrochlorothiazide)

  • Active comparator
    Telmisartan+Amlodipine besylate+Hydrochlorothiazide

    coadministration of Telmisartan, Amlodipine besylate and Hydrochlorothiazide

    Drug: TWYNSTA(Telmisartan+Amlodipine besylate) · Drug: Hydrochlorothiazide

Interventions

  • DrugTAH Tablet (Telmisartan/Amlodipine besylate/Hydrochlorothiazide)

    Telmisartan 80.0 mg, Amlodipine besylate 13.87 mg (Amlodipine 10 mg), Hydrochlorothiazide 25 mg combination-drug would be administered orally once

  • DrugTWYNSTA(Telmisartan+Amlodipine besylate)

    TWYNSTA 2 Tab. 40/5mg(Telmisartan 40 mg, Amlodipine besylate 6.935 mg(Amlodipine 5 mg) would be administered orally once

  • Dichlozid 1 Tab.(Hydrochlorothiazide 25.0 mg) would be administered orally once

06

What researchers measure

Primary outcomes

  1. AUClast

    Time frame: Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 144(Total 18 points)

  2. Cmax

    Time frame: Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 144 (Total 18 points)

07

Study locations

1 site
  • Chonbuk National University Hospital
    Chonbuk, 561-712, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2016 to primary completion in Apr 2016, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2016
First posted
Apr 15, 2016
StartActual
Jan 2, 2016
Primary completionActual
Apr 6, 2016
CompletionActual
Apr 6, 2016
Last update
Jan 26, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02739672
Responsible party
Sponsor
First posted
Apr 15, 2016
Start date
Jan 2, 2016
Primary completion
Apr 6, 2016
Completion
Apr 6, 2016
Last update
Jan 26, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion